Anti-androgen for treating metastatic castration-sensitive prostate cancer

Update: 16 November, 2023

The present invention provides an anti-androgen for treating metastatic castration-sensitive prostate cancer, which includes, but is not limited to 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.

---

File format: PDF

Size: -

MD5 Checksum: 3BC98B26E330752223FD4E7A968CF9F2

Publication date: 16 November, 2023

Downloads: -

PDF Link: Anti-androgen for treating metastatic castration-sensitive prostate cancer PDF